> ImmunOs raised CHF 15 million ($15 million) to complete first-in-human trials of a cancer drug. Pfizer Ventures co-led the series A with BioMedPartners. Release
> Genmab shared early data on its CD3xCD20 bispecific. With dose escalation still ongoing, Genmab has seen a 37% response rate. Statement
> Oryzon presented updated data on iadademstat in acute myeloid leukaemia. Three-quarters of patients have responded to the drug. Release
> Newron Pharmaceuticals delayed a readout from its phase 3 Rett syndrome trial. Analysts were expecting the data to drop imminently, but the results will remain blinded until after a meeting with the FDA. Statement
> Oncopeptides published updated pivotal data on melflufen in multiple myeloma. The Swedish company is expected to file for approval next year. Release
> Bioncotech Therapeutics detailed plans to test BO-112 in combination with Keytruda. Statement